Corrigendum to: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (Clinical Pharmacology & Therapeutics, (2017), 101, 3, (341-358), 10.1002/cpt.602)

Clin. Pharmacol. Ther. 101, 341–358 (2017); doi:10.1002/cpt.602. On page 344, under the heading “Cleveland Clinic's Personalized Medication Program”, the gene drug pair reported as “HLA-B*1502-abacavir” should be “HLA-B*5701-abacavir”. In the first row of Table 1 on page 347, under the column heading “Drug-gene pairs…”, the drug-gene pair “HLA-B*1501/abacavir” should be “HLA-B*5701/abacavir”. In Table 2 on page 353, in the “Antiepileptic” row, under the “Clinically relevant genetic interaction” column, “HLA-B*5701” should be “HLA-B*1502”. The authors regret these errors and thank Dr. Francesco Rucci for bringing them to their attention.